This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q65375798
rdf:type
wikibase:Item
schema:description
klinisch onderzoek clinical trial клінічне випробування ensayu clínicu
rdfs:label
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
skos:prefLabel
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
schema:name
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
p:P1476
wds:Q65375798-12D4E5F5-036E-4911-8092-52D8C8800D4E
wdt:P1476
Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL)
p:P582
wds:Q65375798-46BB2DB1-449A-47AB-81B0-6525C0A379B9
wdt:P582
2014-08-01T00:00:00Z
p:P31
wds:Q65375798-D1345201-F866-48C0-BDED-CBBD563646F6
wdt:P31
wd:Q30612
p:P580
wds:Q65375798-86E7C435-A8F4-46E0-A1AB-9D4381C71797
wdt:P580
2010-01-01T00:00:00Z
p:P17
wds:Q65375798-B3BC7536-FCFD-4C43-BD4F-D90DD9E88205
wdt:P17
wd:Q145
p:P6153
wds:Q65375798-B0D3BA31-CC7B-448C-970C-B01E2E227D4C wds:Q65375798-6621CC0B-B4AB-4487-8576-928BB3744943 wds:Q65375798-82B3C120-CDF2-40DE-B0CC-85DDDBEF44BF wds:Q65375798-482EFA61-0E3C-406B-8F82-88D148220875 wds:Q65375798-52F9CC3E-12D0-4196-9649-6867E16CFDB9 wds:Q65375798-5FE12A19-7AED-4131-9737-E9CA1E313C37 wds:Q65375798-16D12112-90BD-47D6-8050-3E8911BB7E29 wds:Q65375798-39DBE7A7-8E08-4BEB-8515-472677237A51
wdt:P6153
wd:Q7063615 wd:Q837164 wd:Q4865798 wd:Q7374195 wd:Q18389069 wd:Q6516115 wd:Q25188472 wd:Q1035745
p:P1813
wds:Q65375798-61883FD7-62DC-48E4-B4EB-70DB3D844BCA
wdt:P1813
MARALL
p:P4844
wds:Q65375798-EC039E69-2CD2-4973-8F6B-55D7D1684B1B wds:Q65375798-16796A07-9D61-41BB-9B79-723AF1EB2BE4
wdt:P4844
wd:Q3730737 wd:Q50429626
p:P2899
wds:Q65375798-2478B92E-195A-47DA-8330-9FFD3468E77C
wdt:P2899
16
p:P1050
wds:Q65375798-AD5806E5-5362-449E-93D0-7828D73EC6D0 wds:Q65375798-4CDD43F0-1299-4E95-99D5-8C491A0FD4BB
p:P859
wds:Q65375798-055837E6-24A9-4987-8AC7-2FA79BCBBFAB
wdt:P1050
wd:Q29496 wd:Q1016605
wdt:P859
wd:Q195668
p:P1132
wds:Q65375798-CA275116-872F-4A4D-AF48-57F7765D1E74
wdt:P1132
55
p:P8363
wds:Q65375798-FA94E0F9-F49F-49F1-8F0E-4B7716451BB2
wdt:P8363
wd:Q78089383
p:P3098
wds:Q65375798-8CD9964A-98CD-4E92-8908-D8449A24B86D
wdt:P3098
NCT01279707
p:P6099
wds:Q65375798-8AC4FA11-9879-42E5-961B-6E2067F2D812 wds:Q65375798-05A4E2C7-DE29-4F67-A620-AF6CB9FC3DE0
wdt:P6099
wd:Q5452194 wd:Q42824440